Literature DB >> 26427590

Long-Term β-Blocker Therapy Decreases Blood Lactate Concentration in Severely Septic Patients.

Julie Contenti1, Céline Occelli, Hervé Corraze, Fabien Lemoël, Jacques Levraut.   

Abstract

OBJECTIVES: Measurement of blood lactate concentration in the early management of sepsis is an important step in severity assessment. High blood lactate levels in the early phase of sepsis have classically been thought to be related to tissue hypoxia, but other factors could intervene. We hypothesized that the activation of glycolysis through β-adrenergic stimulation by endogenous catecholamines plays an important role in lactate production and that long-term β-blocker therapy could affect the lactate concentration in patients with severe sepsis and septic shock.
DESIGN: Retrospective cohort study.
SETTING: Emergency department. PATIENTS: Two hundred sixty patients with severe sepsis or septic shock were included. Twenty-five percent were previously treated with β-blockers.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We recorded initial vital signs, the source of infection, mortality at 28 days, blood lactate concentration, and Predisposition Insult Response of Organ failure and Sequential Organ Failure Assessment scores using an electronic database. Blood lactate concentration was significantly lower in patients previously treated with β-blockers (3.9 ± 2.3 mmol/L vs 5.6 ± 3.6 mmol/L; p < 0.001). This difference was still significant after controlling for mortality (p < 0.005), for the level of the Predisposition Insult Response of Organ failure (p < 0.05) and Sequential Organ Failure Assessment (p < 0.05) scores, and for the source of infection (p < 0.05). Nearly four times more patients treated with β-blockers had normal blood lactate levels (p< 0.001). Only two factors were significantly and independently associated with normal blood lactate concentration during severe sepsis and septic shock: survival (p = 0.03) and β-blocker therapy (p = 0.01).
CONCLUSIONS: Long-term β-blocker therapy decreases blood lactate concentration of severely ill septic patients at presentation. We conclude that the use of blood lactate measurement as a triage tool in the initial assessment of septic patients with β-blocker therapy may underestimate the severity of the sepsis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26427590     DOI: 10.1097/CCM.0000000000001308

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Outpatient beta-blockers and survival from sepsis: Results from a national cohort of Medicare beneficiaries.

Authors:  Kathleen E Singer; Courtney E Collins; Julie M Flahive; Allison S Wyman; M Didem Ayturk; Heena P Santry
Journal:  Am J Surg       Date:  2017-06-24       Impact factor: 2.565

Review 2.  Lactate, a useful marker for disease mortality and severity but an unreliable marker of tissue hypoxia/hypoperfusion in critically ill patients.

Authors:  Shigeki Kushimoto; Satoshi Akaishi; Takeaki Sato; Ryosuke Nomura; Motoo Fujita; Daisuke Kudo; Yu Kawazoe; Yoshitaro Yoshida; Noriko Miyagawa
Journal:  Acute Med Surg       Date:  2016-05-16

3.  The microcirculation and its measurement in sepsis.

Authors:  Matthew Charlton; Mark Sims; Tim Coats; Jonathan P Thompson
Journal:  J Intensive Care Soc       Date:  2016-11-10

4.  The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review.

Authors:  Kaiquan Tan; Martin Harazim; Benjamin Tang; Anthony Mclean; Marek Nalos
Journal:  Crit Care       Date:  2019-09-04       Impact factor: 9.097

Review 5.  Mitigating the stress response to improve outcomes for older patients undergoing emergency surgery with the addition of beta-adrenergic blockade.

Authors:  Shahin Mohseni; Bellal Joseph; Carol Jane Peden
Journal:  Eur J Trauma Emerg Surg       Date:  2021-04-13       Impact factor: 2.374

Review 6.  The value of blood lactate kinetics in critically ill patients: a systematic review.

Authors:  Jean-Louis Vincent; Amanda Quintairos E Silva; Lúcio Couto; Fabio S Taccone
Journal:  Crit Care       Date:  2016-08-13       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.